secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2024-03-27T23:59:59+00:00
Accession:  0001326190-24-000006
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune reports Q4 net loss $31.6M; positive pemvidutide body composition data; HepTcell discontinued
--------------------------------------------------------------------------------

- Net loss $31.6M ($0.54/share) for Q4 2023, including $12.4M impairment for discontinued HepTcell program.
- Cash $198.0M; body composition: 74.5% weight loss from fat, 25.5% from lean mass on pemvidutide.
- MOMENTUM: 15.6% mean weight loss at 48 weeks on 2.4 mg pemvidutide; >30% achieved ≥20% weight loss.
- IMPACT Phase 2b MASH trial enrollment ongoing; topline 24-week data expected Q1 2025.
- HepTcell development stopped; overall response in Phase 2 insufficient to warrant further advancement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000132619024000006/0001326190-24-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000132619024000006/alt-20240327x8k.htm
  HTML page:      https://secwatch.observer/filing/0001326190-24-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer